Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

Merck KGaA. (3/7/18). "Press Release: Merck Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis". Darmstadt.

Organisation Organisation Merck KGaA
  Group Merck (DE) (Group)
Products Product evobrutinib (M2951)
  Product 2 clinical research
Person Person Rossetti, Luciano (Merck (DE) 201407– Global Head RnD at Merck Serono before Merk Sharp & Dohme)
     


> Primary endpoint met for evobrutinib (Bruton’s Tyrosine Kinase Inhibitor- BTK) in relapsing multiple sclerosis (MS)

> First proof of concept for BTK inhibitor in MS


Merck, a leading science and technology company, today announced positive results from its Phase IIb study of evobrutinib (Bruton’s Tyrosine Kinase Inhibitor – BTK) in relapsing multiple sclerosis (MS). The study has met its primary endpoint, demonstrating that evobrutinib resulted in a clinically meaningful reduction of gadolinium enhancing T1 lesions measured at weeks 12, 16, 20 and 24 in comparison to patients receiving placebo.

“We are encouraged by these early positive results of evobrutinib in relapsing MS,” says Luciano Rossetti, Head of Global Research & Development at the Biopharma business of Merck. “The trial will continue so as to further inform our clinical development strategy for evobrutinib in MS.”

Details on this clinical study can be found on ClinicalTrials.gov.

Evobrutinib, discovered by Merck, is also in Phase IIb studies in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).


For more information, please contact Friederike Segeberg
+49 6151 72-6328


About evobrutinib

Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It is an oral, highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.


Merck in Immunology

Merck has a long-standing legacy in immunology, with significant R&D and commercial experience in multiple sclerosis. Merck’s robust immunology pipeline focuses on discovering new therapies that have the potential to modulate key pathogenic mechanisms in chronic diseases such as MS, systemic lupus erythematosus (SLE) and forms of arthritis, including rheumatoid arthritis (RA) and osteoarthritis (OA).


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

   
Record changed: 2018-03-22

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top